Whitepaper: SARS-CoV-2 vaccines and biosafety
Upholding biosafety standards in coronavirus vaccine development and manufacturing despite the acute worldwide need.
Patient safety comes first. This is particularly important for vaccines, which are also used on healthy individuals. On the basis of the regulatory framework, this article focuses on some of the main challenges in proving that a vaccine is both safe in principle and manufactured in a way that ensures patient safety. It also points to some general obstacles that stand in the way of vaccine development.
Related content from this organisation
- Has the threat of waiving COVID-19 vaccine intellectual property rights had its desired effect?
- 2021 a pivotal year for personalised neoantigens, says GlobalData
- Collaboration to develop neurostimulator for inflammatory disease treatment
- Brochure: Welcome to bioprocessing – pathways for pioneers
- Short talk: How EN 17141 impacts active air sampler validation